Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):e10-2. doi: 10.1097/QAI.0000000000000401.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives
  • Adult
  • Aged
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Drug Therapy, Combination
  • Emtricitabine
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Nitriles / administration & dosage
  • Organophosphonates / administration & dosage
  • Pyrimidines / administration & dosage
  • Rilpivirine
  • Tenofovir
  • Young Adult

Substances

  • Anti-HIV Agents
  • Nitriles
  • Organophosphonates
  • Pyrimidines
  • Deoxycytidine
  • Tenofovir
  • Rilpivirine
  • Emtricitabine
  • Adenine